Tizaro_Tirzepatide SC Injection  7.5 mg/0.5 ml, 5mg/0.5ml, 2.5mg/0.5ml, pre-filled syringe:

Tirzepatide_Tizaro is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide_Tizaro is administered via subcutaneous injections (under the skin). In the United States, it is sold under the brand name Mounjaro for diabetes treatment, and Zepbound for weight loss and treatment of obstructive sleep apnea.

Tirzepatide_Tizaro is a gastric inhibitory polypeptide analog and GLP-1 receptor agonist.The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.

Tirzepatide was approved for treatment of diabetes in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022, and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It was approved by the FDA for weight loss in November 2023.In November 2023, the UK Medicines and Healthcare products Regulatory Agency revised the indication for tirzepatide_Tizaro (as Mounjaro) to include the treatment for weight management and weight loss.In December 2024, the FDA revised the indication for tirzepatide (as Zepbound) to include the treatment of moderate to severe obstructive sleep apnea.

Tirzepatide_Tizaro (as Mounjaro) is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

Tirzepatide_Tizaro (as Zepbound) is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition; and to treat moderate to severe obstructive sleep apnea in adults with obesity.

Tirzepatide_Tizaro has demonstrated significant benefits in obese patients with a common type of heart failure, preserved ejection fraction (HFpEF) in a phase III trial. Over two years, tirzepatide_Tizaro reduced the risk of major complications, including urgent heart failure visits, hospitalizations, increased diuretic treatment, and cardiovascular-related deaths, by 38% compared to placebo.

tirzepatide_Tizaro reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight.

#Alecnib150mg_Alectinib_56Capsuls,

#Acaluxen_100Mg_Acalabrutinib_60Capsules,

#Alkixen_250 Mg_Crizotinib_60_Capsules,

#Alpesib150mg_Alpelisib_28Tablets,

#Avapag20 Mg_Avatrombopag_28Tablets,

#Azarest300Mg_Azacitidine_14Tablets,

#Caboxen20mg_Cabozantinib_90Capsules,

#Caboxen80mg_Cabozantinib_30Capsules,

#Capmaxen200 Mg_Capmatinib_56Tablets,

#Daconib45Mg_Dacomitinib_30Tablets,

#Elopag25mg_Eltrombopag_14Tablets,

#Elopag50mg_Eltrombopag_14Tablets,

#Eudaxen50 Mg_Diazoxide_100 Tablets,

#Gilternib40Mg_Gilteritinib_90Tablets,

#Hepanib200mg_Sorafenib_Tosylate200mg_28Tablets,

#Ibruxen140_Ibrutinib_120Capsules,

#Ivosenib250Mg_Ivosidenib_60Tablets,

#Laronib100mg_Larotrectinib_30Capsules,

#Laronib25mg_Larotrectinib_30Capsules,

#Lenvaxen10mgLenvatinib_30Capsules,

#LenvaxenmgLenvatinib_30Capsules,

#Lorbrexen100mg_Lorlatinib_30Tablets,

#Maviixen100_40Mg_Glecaprevir100mg_Pibrentasvir40mg_21Tablets,

#Mobonib40Mg_Mobocertinib,

#Niranib100mg_Niraparib_30Capsules,

#Olanib150mg_Olaparib_120Capsules,

#Olanib 50mg_Olaparib_112Capsules,

#Osimert80mg_Osimertinib_30Tablets,

#Palboxen125mg_Palbocilib_21Tablets,

#Ponaxen15mg_Ponatinib_30Tablets,

#Ponaxen45mg_Ponatinib_30Tablets,

#Prostaxen60mg_Apalutamide_30Tablets,

#Resiliva80mg_Resmetirom_30Tablets,

#Selcaxen40mg_Selpercatinib_30Tablets,

#Selinex20 Mg_Selinexor_16Tablets,

#Sotoxen120mg_Sotorasib_56Tablets,

#Tivoxen134Mg_Tivozanib_21Capsules,

#Tofaxen5mg_Tofacitinib_14Tablets,

#Tucaxen150mg_Tucatinib_30Tablets,

#Ventoxen_100mg_Venteoclax_60Tablets,

#Crizocent250mg_Crizotinib_60Capsules,

#Ibrucent140mg_Ibrutinib_90Capsules,

#Osicent80mg_Osimertinib_30Tablets,

#Palbocent125_Palbociclib_21Capsuls,

#Panovir_Sofosbuvir_Velpatasvir_28Tablets,

#Tofacent5mg_Tofacitinib_60Tablets,

#Barinib2Mg_Baricitinib-2Mg_30Tbs,

#Barigen4Mg_Baricitinib_4Mg_30tablets,